Opinion

Video

Quality of Life in Patients with Atopic Dermatitis and Patient-Reported Outcomes

Shawn Kwatra, MD, discusses the effects of poorly controlled or severe atopic dermatitis on patients’ quality of life and how to measure patient-reported outcomes.

Video content above is prompted by the following questions:

  • What are the effects of poorly controlled/severe atopic dermatitis (AD) on patient’s quality of life (QoL)?
  • In your clinical experience, which patient-reported outcome (PRO) in AD most impacts patients’ quality of life? (Itch control, skin appearance, sleep improvement, others)?
  • How do you measure PRO outcomes in your clinical practice?
    • How often is treatment satisfaction influenced by achievement of PRO targets?
Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.